Schrodinger (NASDAQ:SDGR) Stock, Quote.Headers.trade-ideas

Schrodinger

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Business,Partnership,Meeting,Concept.,Image,Businessmans,Handshake.,Successful,Businessmen,Handshaking

Earnings

Equities

News

Guidance

Health Care

Contracts

Small Cap

Movers

General

ARKG

SDGR

Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will receive $150 million upfront and eligible to receive up to approximately $2.3 billion in milestone payments plus royalties.

Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details

Etsy photo by Sergei Elagin on Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

APPN

CTMX

DASH

EBAY

ETSY

FRSH

FSLY

HDSN

PAYC

QRVO

RELY

WOLF

Etsy Reports Downbeat Earnings, Joins Fastly, DoorDash And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Penny Stocks

Intraday Update

ADIL

AGFY

AMRN

ARRY

AUMN

BBWI

BCAN

BEDU

BFLY

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLUE

CMPS

COMM

CRML

CSTL

CTKB

DAVA

DUOL

ENVB

ESTA

FIGS

GRFS

GYRE

HAYW

IHRT

INDP

INSG

IONQ

IRWD

LPSN

MGNI

MIST

MRSN

NARI

NTES

NWTN

OCEA

OKTA

ORIC

PSTG

PZZA

QURE

RNLX

RVNC

SCTL

SHLS

SIDU

SNOW

STER

STKL

SWIM

TASK

VERX

VLCN

XMTR

Shares of  Butterfly Network, Inc.  (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Schrodinger Inc

Schrödinger (SDGR) Q3 2024 Earnings Call Transcript

Schrödinger gains on Novartis deal despite Q3 miss

Analyst Brendan Smith from TD Cowen maintained a Buy rating on Schrodinger (SDGR – Research Report) and keeping the price target at $33.00. Brendan...

Positive Outlook for Schrödinger: Buy Rating Based on Strategic Partnerships and Growth Potential

In a report released today, Scott Schoenhaus from KeyBanc maintained a Buy rating on Schrodinger (SDGR – Research Report), with a price target of $...

KeyBanc Keeps Their Buy Rating on Schrodinger (SDGR)

BMO Capital raised the firm's price target on Schrodinger (SDGR) to $28 from $25 and keeps an Outperform rating on the shares. The company reported...

Schrodinger price target raised to $28 from $25 at BMO Capital

Goldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 resul...

Schrodinger price target raised to $28 from $27 at Goldman Sachs

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on SDGR stock, giving a Buy rating yesterday. Mani Foroohar has given hi...

Schrodinger's Strategic Collaborations and Financial Position Bolster Buy Rating Amid Market Confidence and Future Growth Potential

Schrodinger (SDGR) announced that it is broadening and accelerating its initiative to expand the company's computational platform to predict toxico...

Schrodinger gets additional funding to expand toxicology risk initiative

Schrödinger: Positive Signs Despite The Share Price Decline

Stocks with improving and deteriorating 'TechniGrade' by Piper Sandler

ABCL

ACCD

AMRX

APPF

AVDX

AVGO

BMBL

BOWL

CHGG

DECK

ESTC

FIVN

HSIC

JNPR

KRMD

MKTX

NBHC

NRIX

NVDA

NVSEF

OSCR

ROKU

RSKD

Press Releases

Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

Schrödinger to Present at Jefferies London Healthcare Conference

Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

Schrödinger Reports Third Quarter 2024 Financial Results

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Scienture Holdings

Simulations Plus

Sophia Genetics

TruBridge

Teladoc Health

Veeva Systems

Waystar Holding

BMO Capital

Morgan Stanley

Keybanc

Leerink Partners

Citigroup

Comments

Schrodinger

Schrodinger (SDGR) Forecast

Schrodinger (NASDAQ:SDGR) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga